Oragenics, Inc. Announces Private Placement

Oragenics, a UF startup, is partnering with healthcare investors. They've privately placed 404,728 shares of common stock and 404,728 shares of Series E Mirroring Preferred Stock to fight infectious diseases, including coronaviruses.

Targeting a Human Protein To Squash SARS-CoV-2 and Other Viruses

More than two years into the COVID-19 pandemic, people are realizing that the “new normal” will probably involve learning to co-exist with SARS-CoV-2. Some treatments are available, but with new variants emerging, researchers are looking toward new strategies. In ACS Infectious Diseases, scientists now report that apratoxin S4, an anticancer drug candidate that targets a human protein, can interfere with the replication of many viruses, including SARS-CoV-2 and influenza A, offering a possible pan-viral therapy.

Oragenics Announces Publication of Positive Data for Its Nt-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports

UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, a biotech company dedicated to fighting infectious diseases including coronavirus, announces the publication of an article co-authored by Oragenics and collaborators at Inspirevax and the National Research Council of Canada (“NRC”) Human Health Therapeutics Research Centre in Scientific Reports, a Nature journal.

Oragenics To Participate at the World Vaccine Congress Washington 2022

Oragenics, Inc. (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including coronavirus, announced that Kimberly Murphy, a member of the Company’s Board of Directors, will attend the upcoming World Vaccine Congress Washington that will be held on April 18-22 to showcase the Company’s lead product, NT-CoV2-1, an intranasal vaccine candidate, and to pursue business development opportunities.
1 2 3 18